The Cancer Institute Hospital of JFCR
Tokyo, Japan
40 recruiting
Showing 1–20 of 61 trials
Recruiting
Phase 1Phase 2
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Locally Advanced or Metastatic Solid Tumors
Astellas Pharma Global Development, Inc.392 enrolledNCT07730021
Recruiting
Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
BioNTech SE558 enrolled155 locationsNCT07173751
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Genentech, Inc.186 enrolledNCT04910568
Recruiting
Phase 3
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.500 enrolled249 locationsNCT06901531
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb474 enrolled91 locationsNCT07293351
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled281 locationsNCT07221357
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled320 locationsNCT06561386
Recruiting
Phase 3
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Multiple Myeloma
Hoffmann-La Roche380 enrolled15 locationsNCT07555938
Recruiting
Phase 3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Small Cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.480 enrolled76 locationsNCT07218146
Recruiting
Phase 1Phase 2
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
Bayer450 enrolled60 locationsNCT06914128
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Ovarian CancerPlatinum-sensitive Ovarian CancerPSOC
Genmab544 enrolled16 locationsNCT07225270
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company800 enrolled346 locationsNCT07174336
Recruiting
Phase 1
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Breast Cancer
Eli Lilly and Company260 enrolled50 locationsNCT05307705
Recruiting
Phase 1
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung Cancer+1 more
Eli Lilly and Company340 enrolled33 locationsNCT06561685
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Non-small Cell Lung Cancer
Hoffmann-La Roche320 enrolled71 locationsNCT05789082
Recruiting
Phase 1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Lymphoma, Non-HodgkinB-cell LymphomaWaldenstrom Macroglobulinemia+4 more
Eli Lilly and Company215 enrolled50 locationsNCT07101328
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled366 locationsNCT06890598
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled161 locationsNCT07221149
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled260 locationsNCT06793215